A randomised Phase II study of carboplatin with or without the addition of the ETAR inhibitor ZD4054 as treatment for patients with metastatic breast cancer

Cardiff University (UK)0 个研究点目标入组 138 人开始时间: 2010年5月18日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Patients aged = 18
•2. Histological or cytological diagnosis of breast cancer
•3. Metastatic disease
•4. No more than 2 prior lines of chemotherapy treatment for metastatic breast cancer
•5. Life expectancy greater than 3 months
•6. Patients must have previously received or be ineligible for a taxane
•7. Informed consent
•8. Adequate haematological, renal and hepatic function.
•9. At least one measurable lesion on Computed Tomography (CT) scanning

•1. Previous treatment with platinum based chemotherapy
•2. Known brain or leptomeningeal metastases
•3. Any co-existing medical condition that, in the investigator?s judgement, may substantially increase the risk associated with the patient?s participation in the study or potentially hamper compliance with the study protocol and follow-up schedule
•4. Concomitant medication unsuitable for combination with trial medication
•5. Concomitant administration of potent CYP3A inhibitors, specifically:
•5.1. Protease inhibitors (atanazavir, indinavir, nelfinavir, ritonavir, saquinavir)
•5.2. Macrolide antibiotics (clarithromycin, telithromycin)
•5.3. Azole antifungals (ketoconazole, itraconazole, voriconazole)
•5.4. Nefazodone

发起方

Cardiff University (UK)